Your SlideShare is downloading. ×
Nutritional approaches to managing cholesterol and cvd webinar igennus
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Nutritional approaches to managing cholesterol and cvd webinar igennus

1,344
views

Published on

Hosted by with Sophie Tully BSc MSc, 10th October …

Hosted by with Sophie Tully BSc MSc, 10th October

This presentation addresses the role of cholesterol in CVD and the latest evidence into nutritional strategies to manage and treat high cholesterol and support healthy CVD function. Sophie covers the aetiology of CVD and why cholesterol has long been considered an important marker of CVD health and the emergence of newly identified CVD risk factors which may offer a more effective diagnostic tool. Finally she discusses new opinions on nutritional approaches to keep cholesterol levels healthy and prevent CVD events.


0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,344
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
17
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Nutritional approaches to managing cholesterol and CVD. Key messages from the research. Sophie Tully BSc MSc DIPPT
  • 2. What is CVD? Cardiovascular disease (CVD) is a general term that describes a disease of the heart or blood vessels. • Blood flow to the heart, brain or body can be reduced as a result of a: – blood clot (thrombosis) – build-up of fatty deposits inside an artery, leading to the artery hardening and narrowing (atherosclerosis) Types of CVD: • Coronary heart disease • Stroke • Peripheral arterial disease • Aortic disease www.NHS.uk/conditions
  • 3. Risk factors • • • • • • • • Smoking Being physically inactive Being overweight or obese Diabetes Family history of heart disease Ethnic background Sex - men are more likely to develop CVD at an earlier age than women Age - the older you are, the more likely you are to develop CVD • High blood pressure • High blood cholesterol • Stress, alcohol, the type of job you do may also influence your risk of developing CVD www.bhf.org.uk
  • 4. Traditional management methods Antihypertensives: - diuretics - angiotensin-converting enzyme (ACE) inhibitors - beta blockers Blood-thinning medications: - aspirin therapy - warfarin Cholesterol-lowering medications: - statins - fibrates
  • 5. • Today 6-7million UK inhabitants are on daily statins! • In the US between 2005-2009 nearly 20% of the population were taking antihypertensive medication • Approximately 2 million US inhabitants take blood thinners daily • Common side effects of these drugs include: water retention, depression+/anxiety, headache, dry mouth, insomnia, chest pain, impotence, hair loss, skin rash, nausea / diarrhoea, kidney & liver damage……….
  • 6. Recommended risk reduction • • • • • • Exercise Lose weight Reduce stress Stop smoking Eat a low fat diet Reduce cholesterol intake Ideal lipid profile (according to the BHF): Total cholesterol HDL cholesterol LDL cholesterol Triglycerides 4 mmol/L >1 mmol/L < 2 mmol/L <1.7 mmol/L
  • 7. The truth about fat Fat-free = • flavour, texture and satisfaction free • sugar and artificial ingredients added to make product edible! Fat is: • an essential membrane component of every single cell in the body (including saturated fat!) • a highly efficient source of fuel that humans are designed to thrive on • an energy store, insulator to protect our vital organs, acts as a messenger, aids protein function, contributes to normal growth, immune function, reproduction and other aspects of basic metabolism
  • 8. The truth about Cholesterol Low cholesterol intake = • Inadequate supply of the building blocks for hormones • Inability to produce bile acids • Inability to synthesise Vitamin D Now widely recognised that dietary intake of cholesterol has very little impact on the body’s cholesterol levels The body requires a continuous supply of cholesterol and possesses the ability to synthesise cholesterol itself
  • 9. Per Nutrition information medium size egg Per 100g What about eggs? 66kcal 131kcal Protein 6.4g 12.6g Carbohydrate of which sugars trace trace Cutting out eggs cuts out a cheap, healthy and widely available source of lots of nutrients that contribute to reaching vital RDAs Fat of which saturates monounsaturates polyunsaturates 4.6g 1.3g 1.7g 0.7g 9.0g 2.5g 3.4g 1.4g Sodium 78mg 154mg Energy Delicious, nutritious and filling! http://healthyegg.co.uk/nutritionalcomposition
  • 10. The ‘evidence’ for fat and cholesterol • Early studies (1980) by Ancel and Keys found: – total fat does not affect CHD death – but % energy from saturated fat does correlate with CHD • Replacing saturated fat with any nutrient = reduced LDL = good for CVD • However, 2 studies in 2010 say otherwise: – meta-analysis, just under 350,000 subjects found NO link between saturated fat intake and coronary events – Japanese cohort following 58,453 women over 14 years found those eating ‘ideal’ 2.511g saturated fat daily had 45% increased stroke risk and 22% increased CVD vs those eating more (18g) daily • Today ~50% of our calories come from carbohydrate but CVD risk is still on the rise!
  • 11. The ‘evidence’ for fat and cholesterol • 1% increased energy intake from sat fat vs CHO = increased LDL by 0.03 mmol/L • 5% increased energy CHO vs sat fat = 7% increased CHD • Increased sat fat intake = increased LDL particle size • Increased CHO intake = increased triglycerides and reduced HDL and reduced LDL particle size = increased atherosclerosis risk – small LDL particles = increased vessel wall damage and penetration – reduced binding capacity of LDL particles to receptors = remain in circulation for longer – more susceptible to oxidative damage
  • 12. The ‘evidence’ for fat and cholesterol • GI of CHO source very important: – high GI = 33% increased heart attack risk, med GI = no effect, low GI = small reduced risk – low GI diet is typically high in vegetables, fruit, legumes and unprocessed grains = high in vitamins, minerals, phytonutrients and fibre – all essential for CV health The Health delusion: a big fat mistake, Glen Matten and Aidan Goggins
  • 13. What really works? Polyunsaturated fatty acids (PUFAs) • A 5% switch from sat fat to PUFA = 10% reduced CHD • Replacing CHO with PUFA = most favourable CHD outcomes • Thus increasing PUFA = CHD benefits • But two types of PUFA – omega-6s are abundant in plant oils, animal protein, nuts and grains – omega-3s found in small amounts in foods, mainly fish
  • 14. PUFAs continued… • Omega-6 intake already around upper recommended limits but omega-3 intake generally low • Studies looking at increasing omega-6 only vs omega-3&6 intake found: – increasing omega-6 intake only = small increase CHD risk • Thus benefits of PUFA intake mainly down to omega-3s – specifically EPA & DHA found in fish Why?
  • 15. PUFAs continued… EPA and DHA have been shown to be/offer: – anti-inflammatory – vasodilator activity – triglyceride lowering – reduced platelet aggregation – plaque stabilisation – antiarrhythmic – hypotensive effects (Halcox, 2010) Importance of omega-3s in CV function: • The omega-3 index is an indicator of cardiovascular disease risk • RBC omega-3 levels and the AA to EPA ratio may be a more potent risk factor for sudden cardiac death than high blood cholesterol levels or creactive protein (Dawczynski et al., 2010)
  • 16. Inflammation and CVD • PUFAs – strongly linked to control of the inflammatory response • Optimal EPA (and DHA) levels = healthy inflammatory control • AA intake important for inflammatory control • AA to EPA ratio = very useful biomarker of inflammation and chronic disease risk • Stress and high GI foods – linked to CVD and both increase inflammation • Inflammation leads to increased susceptibility to damage of blood vessel walls and reduced cellular communication (Boer, Van Wetten and Pruiboom, 2012)
  • 17. AA to EPA ratio is a direct measure of inflammation By modifying diet we can influence the ratio of pro-inflammatory (from AA) to anti-inflammatory eicosanoids (from EPA)
  • 18. Conditions associated with a high AA to EPA ratio • • • • • • • • • Depression Bipolar disorder Schizophrenia Myalgic encephalomyelitis Fibromyalgia Chronic pain syndromes Diabetes Cardiovascular disease Cancer • • • • • • Inflammatory disorders Inflammatory bowel disease: (Crohn’s disease, ulcerative colitis) Neurodevelopmental disorders: (autism, dyslexia, dyspraxia, ADHD) Alzheimer’s disease Huntington’s disease Skin conditions: (eczema, psoriasis, dermatitis)
  • 19. EPA, DHA and CVD – the research • Red blood cell omega-3 levels strongly inversely associated with sudden cardiac death • Daily fish oil associated with reduced risk of all cause mortality and secondary coronary events in post-myocardial infarction cohorts • Fish oil supplementation resulted in reduced risk of death or hospitalisation due to CV events • Recommended minimum 1g daily intake of fish oil from supplements predominantly EPA or oily fish intake – fish consumption associated with high toxin levels and large volumes needed (Weitz et al., 2010)
  • 20. EPA and DHA benefits shared or different? • 2011 two very comprehensive reviews were published • EPA alone = reduced TGs and risk of coronary events and conditions • DHA alone = reduced TGs, increased LDL particle size and reduced BP and HR • Either alone or in combination, contribute differentially to reduced inflammation, oxidative stress and platelet aggregation, enhanced cardiac and arterial function seen with omega-3 intake • Both reviews concluded evidence on the whole for the enhanced effects of one fat over the other on any CV marker was poor due to low number of studies, under-powered and poor design
  • 21. EPA and DHA benefits shared or different? Overall conclusions: In order to determine which type of omega-3 and dose would be optimal requires many more studies, as response varies dependant on the individual and their specific CVD profile. It was noted however that EPA levels were more impacted by increasing intakes than DHA, suggesting DHA in the cell may be more stable and thus potentially the need to supplement is not so great.
  • 22. A new wave of pure omega-3 studies Following these reviews numerous pure oil studies were carried out: 1) JELIS study found – 1.8g/day of ethyl-EPA in just under 20,000 hypercholesterolemic subjects randomised to EPA + statins or statins alone = 19% reduced incidence of major CVD – that increasing EPA and reducing AA:EPA ratio were both useful in preventing coronary artery disease
  • 23. A new wave of pure omega-3 studies 2) Tani et al., 2013 – Hypertriglyceridaemia patients randomised to 2 x 900mg ethyl-EPA for 6 months had significantly increased LDL particle size, reduced serum TGs and non-HDL cholesterol vs no significant changes in controls – LDL particle size at 6 months positively correlated with serum EPA and negatively correlated with AA:EPA ratio – 6 month AA:EPA ratio was found to be better than any other marker at predicting LDL particle size
  • 24. What next? • Importance of EPA as stand alone and co-therapy for CVD now well established • In 2012 the FDA approved a high purity ethyl-EPA product for use in treating hypertriglyceridaemia • Phase III placebo controlled clinical trials using ‘Vascepa™’ further support the benefits of ethyl-EPA in managing and treating CVD
  • 25. Vascepa™ trials: • ANCHOR & MARINE looked at role of EPA on inflammatory markers associated with CVD and atherosclerosis in hypertriglyceridaemic patients taking statins for cholesterol control. • Both studies randomised subjects to 12 weeks of taking 4 or 2g EPA or placebo daily • Results showed 4g EPA reduced TGs, non-HDL cholesterol and other markers of atherosclerosis without increasing total LDL • The ANCHOR study used predominantly (>70%) diabetic subjects and showed 4g EPA daily significantly improved lipid profiles and lipid related markers without negatively impacting glycaemic control
  • 26. There’s more to come! • REDUCE-IT study currently ongoing • Aim is to determine efficacy of IPE in preventing CV events in high risk patients on statins • Overall Vascepa™ has been hailed as safe, effective and a new alternative with potential benefits over existing treatments
  • 27. Igennus CVD support protocol Pharmepa Step 1: Restore 2 capsules = 1g pure ethyl EPA Vitamin E for antioxidant protection Designed to • Increase cellular EPA levels quickly • Restore a healthy AA:EPA ratio • Reduce the production of pro-inflammatory products • Increase the production of anti-inflammatory products • Support cardiovascular health and cholesterol levels
  • 28. VESIsorb Ubiquinol-QH CoQ10 and cholesterol-lowering drugs • Igennus is the only independent manufacturer of reductase is an enzyme that plays critical role Based in • HMG-CoAspecialist Fatty Acid ina the UK. in the regulation of cholesterol synthesis, as well as CoQ10 synthesis hub for the Cambridge the medical innovation UK: • HMG-CoA reductase inhibitors, generally known as statins (such as atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin), are - Seven elevated commonly used to treat Seas blood Merck Pharma blocking cholesterol levels by Germany cholesterol biosynthesis; in doing so, they also block CoQ10 Canada - Minami Atrium Pharma biosynthesis - Biocare Elder Pharma India • Taking ubiquinol supplements can correct the deficiency causedSweden - Eskimo 3 Bringwell Pharma by such medications without affecting the medication's positive effects - Equizen Vifor Pharma Swiss on cholesterol levels and can improve statin-induced myopathy
  • 29. Acetyl-CoA HMG-CoA synthase HMG-CoA HMG-CoA reductase inhibitors (statins) HMG-CoA reductase Mevalonate Cholesterol Coenzyme Q10 (ubiquinone)
  • 30. VESIsorb Ubiquinol-QH Faster acting, stronger plasma concentration and longer lasting effects • Igennus is the only independent manufacturer  Unprecedented bioavailability Acid in the UK. Based in of specialist Fatty  Fully reduced ‘bioactive’ form Cambridge the medical innovation hub for the  Solubilised for maximum absorption  NovelUK: VESIsorb® delivery system mimics the natural transport system of the intestine, providing significantly higher plasma concentrations† - delivery Seas Merck Pharma than any other Seven system offering a comparable dose Germany  One capsule Minami a therapeutic dose (100 mg) - daily delivers Atrium Pharma Canada - Biocare Elder Pharma India Enhances energy production Potent antioxidant Supports antioxidant turnover - Eskimo Bringwell Pharma Sweden Enhances cellular communication3Cell cycle support Reduces statin-associated myopathy Cardioprotective Neuroprotective Anti-inflammatory - Equizen Vifor Pharma Swiss
  • 31. Homocysteine Control Sustained Release Homocysteine is an amino acid derivative of methionine, anmanufacturer • Igennus is the only independent essential amino acid obtained from protein-rich foods of specialist Fatty Acid in the UK. Based in The amount of homocysteine in medical a predictive marker Cambridge the the blood is innovation hub for the of cardiovascular health status UK: High levels are Seven Seas - a reliable risk factor for cardiovascular diseaseGermany Merck Pharma - lowers levels Atrium Pharma Canada Homocysteine Minami of nitric oxide, a gas that is critical to maintaining healthy and flexible arterialElder Pharma India walls - Biocare - Eskimo 3 Bringwell affecting Elevated homocysteine directly damages cholesterol, Pharma Sweden arterial walls, causing them to thicken which can lead to - Equizen Vifor Pharma Swiss atherosclerosis
  • 32. Homocysteine Control Sustained Release • Igennus is the only independent manufacturer of specialist Fatty Acid in the UK. Based in for the UK:  Formulated at proven dosages for efficacy Homocysteine ControlTM Sustained Release tablets contain a synergistic blend of bioavailable vitamins B6, B12 and folic acid at precise dosages for maintaining healthy homocysteine levels. Cambridge the medical innovation hub  Highly bioavailable actives - Seven Merck Pharma Germany  Easy-to-swallow tabletsSeas  Suitable for vegetarians & vegans - Minami Atrium Pharma Canada  Sustained release tablets to maintain optimal blood Elder Pharma India concentrations Biocare  Split dosing overcomes bioavailability issues associated with Sweden - Eskimo 3 Bringwell Pharma B12 supplementation - Equizen Vifor Pharma Swiss
  • 33. www.igennus.com 01223 421434 • Igennus is the only independent manufacturer info@igennus.com of specialist Fatty Acid in the UK. Based in Cambridge the medical innovation hub for the UK: - Seven Seas Sophie Tully Merck Pharma Germany Nutrition education manager - Minami Atrium Pharma Canada sophiet@igennus.com - Biocare Elder Pharma India education@igennus.com - Eskimo 3 07908683174 Pharma Sweden Bringwell - Equizen Vifor Pharma Swiss